Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2016 3
2017 2
2018 3
2019 3
2020 1
2021 3
2022 3
2023 1
2024 2
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. Among authors: kassahun h. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. N Engl J Med. 2022. PMID: 36342163 Free article. Clinical Trial.
BACKGROUND: Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. ...CONCLUSIONS: Olpasiran therapy significantly reduced lipoprotein(a) concentrations i …
BACKGROUND: Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA …
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Nicholls SJ, et al. Among authors: kassahun h. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. JAMA. 2016. PMID: 27846344 Clinical Trial.
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, Florio M, Kassahun H, Melquist S, Varrieur T, Haldar SM, Sohn W, Wang H, Elliott-Davey M, Rock BM, Pei T, Homann O, Hellawell J, Watts GF. Koren MJ, et al. Among authors: kassahun h. Nat Med. 2022 Jan;28(1):96-103. doi: 10.1038/s41591-021-01634-w. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027752 Clinical Trial.
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. ...
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly target …
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results.
O'Donoghue ML, Rosenson RS, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. Among authors: kassahun h. J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058. J Am Coll Cardiol. 2024. PMID: 39168564 Free article. Clinical Trial.
METHODS: OCEAN(a)-DOSE (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study) was a phase 2, dose-finding trial that enrolled 281 participants with atherosclerotic cardiovascular disease and Lp(a) >150 nmol/L to 1 of 4 active …
METHODS: OCEAN(a)-DOSE (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study) was a phase 2, dos …
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial.
Rosenson RS, López JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, Park JG, Murphy SA, Knusel B, Wang J, Wilmanski T, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML; OCEAN(a)-DOSE Trial Investigators. Rosenson RS, et al. Among authors: kassahun h. JAMA Cardiol. 2025 May 1;10(5):482-486. doi: 10.1001/jamacardio.2024.5433. JAMA Cardiol. 2025. PMID: 39937508 Free PMC article. Clinical Trial.
A total of 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels greater than 150 nmol/L were included. INTERVENTION: Participants were randomized to receive 1 of 4 active subcutaneous doses of olpasiran vs placebo: (1) 10 mg, administered every 12 week …
A total of 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels greater than 150 nmol/L were included. INTERVENT …
Evolocumab: Considerations for the Management of Hyperlipidemia.
Wiggins BS, Senfield J, Kassahun H, Lira A, Somaratne R. Wiggins BS, et al. Among authors: kassahun h. Curr Atheroscler Rep. 2018 Mar 6;20(4):17. doi: 10.1007/s11883-018-0720-3. Curr Atheroscler Rep. 2018. PMID: 29511875 Review.
Recent results indicate that LDL-C reduction with evolocumab significantly reduces the risk of cardiovascular events and is also associated with atherosclerotic plaque regression. From a safety standpoint, rates of adverse events (AEs), serious AEs, and AEs leading to disc …
Recent results indicate that LDL-C reduction with evolocumab significantly reduces the risk of cardiovascular events and is also asso …
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE).
O'Donoghue ML, G López JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. O'Donoghue ML, et al. Among authors: kassahun h. Am Heart J. 2022 Sep;251:61-69. doi: 10.1016/j.ahj.2022.05.004. Epub 2022 May 16. Am Heart J. 2022. PMID: 35588897 Free article.
BACKGROUND: Data support lipoprotein(a) (Lp[Lp(a)]) being a risk factor for atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that markedly reduces Lp(a) production in hepatocytes. ...These data will be used to determine optimal …
BACKGROUND: Data support lipoprotein(a) (Lp[Lp(a)]) being a risk factor for atherosclerotic cardiovascular disease (ASCVD). Olpasiran …
Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.
Marquis-Gravel G, Roe MT, Turakhia MP, Boden W, Temple R, Sharma A, Hirshberg B, Slater P, Craft N, Stockbridge N, McDowell B, Waldstreicher J, Bourla A, Bansilal S, Wong JL, Meunier C, Kassahun H, Coran P, Bataille L, Patrick-Lake B, Hirsch B, Reites J, Mehta R, Muse ED, Chandross KJ, Silverstein JC, Silcox C, Overhage JM, Califf RM, Peterson ED. Marquis-Gravel G, et al. Among authors: kassahun h. Circulation. 2019 Oct 22;140(17):1426-1436. doi: 10.1161/CIRCULATIONAHA.119.040798. Epub 2019 Oct 21. Circulation. 2019. PMID: 31634011 Review.
Small-Interfering RNA Olpasiran and Apolipoprotein B Particles.
Zimerman A, López JAG, Rosenson RS, Gaudet D, Baum SJ, Park JG, Wang J, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML. Zimerman A, et al. Among authors: kassahun h. JAMA Cardiol. 2025 Dec 1;10(12):1322-1324. doi: 10.1001/jamacardio.2025.4105. JAMA Cardiol. 2025. PMID: 41191372
Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
Forbes C, Quek RG, Deshpande S, Worthy G, Ross J, Kleijnen J, Gandra SR, Kassahun H, Wong ND, Nicholls SJ. Forbes C, et al. Among authors: kassahun h. Curr Med Res Opin. 2016 Jun;32(6):1143-50. doi: 10.1185/03007995.2016.1162775. Epub 2016 Mar 17. Curr Med Res Opin. 2016. PMID: 26949994
Objective Evidence from coronary imaging studies suggests an association between increased atherosclerotic plaque burden and cardiovascular disease (CVD) outcomes. A systematic review was performed to evaluate the relationship between coronary atherosclerotic plaque burden …
Objective Evidence from coronary imaging studies suggests an association between increased atherosclerotic plaque burden and cardiovascul …
26 results